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Ferritin     
Background: Iron deficiency anemia is common in patients on maintenance hemodialysis 
(HD). Serum ferritin is increased in HD patients. Vitamin C supplementation has shown 
to improve functional iron deficiency and anemia in HD patients. 
Objectives: In this study we aimed to evaluate the effect of vitamin C supplementation on 
serum ferritin level.
Patients and Methods: In this randomized clinical trial, 39 HD patients were randomly 
assigned to receive routine therapy with (n = 24) or without (n = 15) vitamin C 500 mg IV 
twice a week after each dialysis session for 2 months. Changes in serum ferritin, iron, total 
iron-binding capacity (TIBC) and transferrin saturation (TS) before and after treatment 
were measured in each group.           
Results: Serum ferritin levels before treatment in case and control groups were 1859 ± 1398.5 
and 2567.5± 1907.8 ng/mL which was significantly decreased to 1084.8± 727.9 and 
1313.5± 1151.5 ng/mL, respectively (P = 0.006 and P = 0.007). Serum iron, TIBC and TS 
did not change significantly in each group after treatment. Comparing the mean changes 
in serum ferritin, iron, TIBC and TS, there was no significant difference between groups.
Conclusions: Vitamin C had no effects on serum ferritin, iron and TS.
ABSTRACT
Implication for health policy/practice/research/medical education:
Iron deficiency anemia is common in patients on maintenance hemodialysis (HD). Serum ferritin is increased in HD patients. 
We observed that administration of  vitamin C 500 mg IV twice a week had no effects on serum ferritin, iron and TS and 
might not improve anemia. 
Please cite this paper as: Bashardoust B, Zakeri A, Jastan M, Amani F, Habibzadeh A, Khatami  F. Impact of  vitamin C 
supplementation on serum ferritin level in hemodialysis patients. J Nephropathol. 2018;7(3):197-200. DOI: 10.15171/
jnp.2018.40.
1. Background 
Iron deficiency anemia is common in patients on 
maintenance hemodialysis (HD) and may be associated 
with poor outcome, including higher death risk (1). 
The pathogenesis of  anemia in chronic kidney disease 
is multifactorial. It can occur in HD patients due to 
shortened erythrocyte survival, continuing blood loss in 
the dialy sis circuit, iron and other nutritional deficiencies, 
hemolysis, the presence of  uremic inhibitors of 
erythropoiesis, and inadequate iron stores. Additionally 
frequently laboratory testing, interventional procedures 
and gastrointestinal bleeding are responsible for anemia 
in HD patients (2,3).
Common laboratory tests used to diagnose iron 
deficiency in HD patients are serum ferritin and 
transferrin saturation (TS) (2). Serum ferritin is both 
an iron storage protein and an acute phase reactant. 
Serum ferritin concentration increases in the presence of 
inflammation, especially in HD patients (4,5).
Vitamin C plays an important role in the kinetics of  iron 
metabolism and the utilization of  iron for red blood cell 
formation. Low vitamin C levels have been reported 
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in HD patients (6). Previous studies have shown 
improvement of  anemia using vitamin C in HD patients 
(7,8). Vitamin C can decrease inflammatory markers (9) 
and hence by improving inflammation, it would improve 
ferritin level which results to improve anemia. 
2. Objectives
In this study we aimed to evaluate the effect of  IV 
vitamin C supplementation on ferritin, iron, TIBC and 
TS levels and anemia in HD patients.
3. Patients and Methods 
In this randomized clinical trial, 39 HD patients for more 
than three months were randomly assigned to receive 
vitamin C (n = 24) or no treatment (n = 15). HD patients 
with serum ferritin >500 ng/mL were selected. Patients 
with a history of  malignancy, active infection (hepatitis, 
tuberculosis), hyperparathyroidism (intact parathyroid 
hormone >3 upper limit normal) or evidence of 
hemolysis (reticulocyte count >2%) were excluded. 
Patients in the intervention group received vitamin C 
500 mg IV twice a week after each dialysis session for 
two months and group control received no injections. 
Before and after two months following treatment, serum 
ferritin, iron, total iron-binding capacity (TIBC) and TS 
were measured. Erythropoietin treatment as well as oral 
or IV iron treatment were similar between groups during 
the study period. 
Before and after treatment, serum levels of  iron and 
ferritin, TIBC and TS were measured and compared 
between groups. Mean percent changes in laboratory 
findings were also measured and compared between 
groups. 
3.1. Ethical issues
The research followed the tenets of  the Declaration 
of  Helsinki and its later amendments. Patients gave 
their written and informed consent to participate in 
this investigation by completing the consent form. 
This research has been granted by Ardabil University 
of  Medical Sciences regarding financial budget, and has 
been approved by the university (ethics code # 0212). 
3.2. Statistical analysis
All data were analyzed using SPSS 17 (version 17; SPSS 
Inc., Chicago, IL). Results are expressed as mean ± SD or 
percentage. The chi-squared test was applied to compare 
categorical variables and independent t test to compare 
continuous variables. Laboratory findings before and 
after treatment in each group were analyzed using paired 
samples t test. Additionally, P values   of  less than 0.05 
were considered statistically significant. 
4. Results
Thirty-nine HD patients were enrolled in the study 
(vitamin C administration [n = 24] or without using 
vitamin C [n = 15] following dialysis sessions). Patients 
in case and control groups had similar age (54.29 ± 16.62 
versus 52.20 ± 16.21 years, P = 0.11) and gender 
distribution (males: 14 [58.3%] versus 9 [60%], P = 0.9). 
Iron profile before and after treatment in each group is 
demonstrated in Table 1. Comparing the results before 
and after treatment in vitamin C and control group, 
only serum ferritin levels were significantly decreased 
(P = 0.007 and P = 0.006, respectively). Before treatment, 
ferritin levels were significantly higher in control group, 
but after treatment there was no significant difference 
between groups. Also, TIBC levels had no significant 
difference between groups before treatment, but 
following treatment, there was a significant difference. 
Changes in serum iron, ferritin, and TIBC and TS 
between groups also had no significant difference. 
Table 1. Iron profile before and after treatment and mean percent change in each group
Vitamin C, (n = 24) Control, (n = 15) P value
Serum Iron
Before 100.8 ± 50.3 91.1 ± 48.6 0.5
After 108.6 ± 26.4 101.9 ± 48.00 0.27
TIBC
Before 309.4 ± 237.2 294.9 ± 185.6 0.08
After 283.4 ± 49.4 272.9 ± 39.2 0.04*
Ferritin
Before 1859 ± 1398.5 2567.5 ± 1907.8 0.01
After 1084.8 ± 727.9 1313.5 ± 1151.5 0.4
Transferrin saturation 
Before 0.41 ± 0.29 0.40 ± 0.28 0.9
After 0.42 ± 0.09 0.41 ± 0.14 0.7
Serum Iron change (%) 13.67 ± 2.91 12.39 ± 1.20 0.7
TIBC change (%) -14.51 ± 5.28 -17.27 ± 11.09 0.3
Ferritin change (%) -46.59 ± 17.23 -47.52 ± 17.36 0.8
Transferrin saturation change (%) 2.50 ± 0.41 2.52 ± 0.28 0.8
*P value is two-sided significant.
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5. Discussion
Anemia is an important complication of  CKD and HD 
which is multifactorial. It is recommended that vitamin C 
supplementation could improve anemia in HD patients. 
Vitamin C has multiple roles including antioxidant, 
immune function and improvement of  the absorption 
of  non-heme iron (10). 
In this study we evaluated the effect of  vitamin C 
supplementation on serum ferritin level and other 
markers. We found no significant difference of  serum 
ferritin, iron, TIBC and TS among groups with and 
without vitamin C treatment. 
Similar to our findings, Petrarulo et al and Ogi et al 
reported the improvement of  functional iron deficiency 
anemia by vitamin C administration, which it had no 
significant effect on levels of  ferritin, iron, TIBC and 
TS (11,12). Other studies were also unable to show any 
benefit in the administration of  vitamin C (13). 
However, recent studies have indicated that vitamin 
C reduces ferritin levels and improves anemia and 
increases iron utilization. Jalalzadeh et al (14) showed 
that intravenous vitamin C 500 mg following after 
each dialysis session reduces ferritin and improves TS. 
Similarly, Shahrbanoo and Taziki (15) reported vitamin 
C 300 mg intravenously following each dialysis session 
reduces ferritin levels, increases TS and improves 
responsiveness to erythropoietin therapy. 
Reducing ferritin levels is important in HD patients to 
improve anemia and response to erythropoietin. Ogawa 
and colleagues (16) reported, serum ferritin levels <90 
ng/mL and TS >20% provides proper iron status. They 
showed better results in anemia therapy in HD patients. 
Hence, finding the proper treatments to reduce serum 
ferritin in HD patients is important. It is possible that 
using constant doses of  vitamin C and not increasing to 
the maximum dose could be a reason for our insignificant 
findings. Additionally, it is possible that vitamin C could 
not show its effects on the low duration of  the therapy 
and longer duration may be necessary. 
6. Conclusions
To conclude, vitamin C administration 500 mg IV twice 
a week had no effects on serum ferritin, iron and TS. 
Further studies are needed to evaluate the effective 
dosage of  vitamin C on improving anemia and ferritin 
levels.
Study limitations
Small proportion of  patients with high ferritin was the 
main limitation of  our study.
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